Diroximel fumarate (Standard)

Diroximel fumarate (Standard) is the analytical standard of Diroximel fumarate (HY-100375) . This product is intended for research and analytical applications. Diroximel fumarate (ALKS 8700) is an orally-active and well-tolerated monomethyl fumarate (MMF) proagent in a controlled-release formulation. Diroximel fumarate is considered as active equivalent to its active metabolite dimethyl fumarate (DMF) . Diroximel fumarate has a favorable safety and efficacy profile, has the potential for the study of multiple sclerosis (MS) . Diroximel fumarate is a Nrf2 activator that alleviate MGO-induced pain hypersensitivity[1][2].

Product Specifications

CAS Number

[1577222-14-0]

Target

Keap1-Nrf2; Reference Standards

Related Pathways

NF-κB; Others

Field of Research

Inflammation/Immunology

Smiles

O=C(OCCN1C(CCC1=O)=O)/C=C/C(OC)=O

Molecular Formula

C11H13NO6

Molecular Weight

255.22

References & Citations

[1]Angela Wehr, et al. Relative Bioavailability of Monomethyl Fumarate after Administration of ALKS 8700 in Healthy Subjects (P1.403) . Neurology. Apr 2018.|[2]Yousuf MS, et al. Diroximel fumarate acts through Nrf2 to attenuate methylglyoxal-induced nociception in mice and decreases ISR activation in DRG neurons. bioRxiv [Preprint]. 2023 Dec 23:2023.12.22.572877.